Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
复制标题
DOI：
10.1038/s41392-020-00301-9
复制
发表时间：
2020-09-02
影响因子：
39.3
通讯作者：
Ye, Lilin
中科院分区：
文献类型：
--
作者：
Chen, Xiangyu;Pan, Zhiwei;Ye, Lilin
COVID-19患者在SARS-CoV-2感染后表现出不同的疾病严重程度。目前尚不清楚COVID-19患者中和抗体（NAb）反应的大小与疾病严重程度之间的相关性。在59名疾病严重程度包括严重、中度、轻度和无症状的康复患者队列中，我们观察到血清中和能力与疾病严重程度呈正相关，特别是严重疾病患者血清中NAb能力最高，而无症状患者缺乏能力。此外，NAb亚型的组成在重症状和轻至中度症状的康复患者之间也存在差异。这些结果揭示了sars - cov -2特异性NAb反应的巨大异质性及其与疾病严重程度的相关性，强调了未来对无症状或轻度疾病康复的COVID-19患者接种疫苗的必要性。
COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.